Spots Global Cancer Trial Database for relapsed and refractory multiple myeloma
Every month we try and update this database with for relapsed and refractory multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | NCT01324947 | Multiple Myelom... | pomalidomide | 18 Years - | Celgene | |
| Study of BCMA CAR-T in Multiple Myeloma | NCT03559764 | Relapsed and Re... | Anti-BCMA CAR T... | 18 Years - 70 Years | Allife Medical Science and Technology Co., Ltd. | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | NCT04155749 | Relapsed and Re... | anitocabtagene-... ARC-T Plus Anti... | 18 Years - | Gilead Sciences | |
| A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies | NCT02223598 | Lymphoid Hemato... Relapsed and Re... | CB-5083 Dexamethasone | 18 Years - | Cleave Biosciences, Inc. | |
| Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | NCT01450215 | Multiple Myelom... | Revlimid | 18 Years - | Karolinska University Hospital | |
| Study of BCMA CAR-T in Multiple Myeloma | NCT03559764 | Relapsed and Re... | Anti-BCMA CAR T... | 18 Years - 70 Years | Allife Medical Science and Technology Co., Ltd. | |
| An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | NCT03601078 | Multiple Myelom... | bb2121 Lenalomide Talquetamab | 18 Years - | Celgene | |
| A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study | NCT01311687 | Multiple Myelom... | pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | NCT03029234 | Relapsed and Re... | Dexamethasone Carfilzomib | 18 Years - | Amgen | |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | NCT06050512 | Relapsed and Re... | Mezigdomide Ixazomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | NCT04155749 | Relapsed and Re... | anitocabtagene-... ARC-T Plus Anti... | 18 Years - | Gilead Sciences | |
| Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT01497093 | Multiple Myelom... | Pomalidomide Bortezomib Dexamethasone | 18 Years - | Celgene | |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | NCT02144038 | Relapsed and Re... | LGH447 BYL719 | 18 Years - | Novartis | |
| Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03477643 | Relapsed and Re... | 18 Years - | PETHEMA Foundation | ||
| BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma | NCT03661554 | Relapsed and Re... | BCMA CAR-T Cell... | 18 Years - 75 Years | The Pregene (ShenZhen) Biotechnology Company, Ltd. | |
| Efficacy Study of CYT997 in Multiple Myeloma | NCT00664378 | Relapsed and Re... | CYT997 | 18 Years - | Gilead Sciences | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03000452 | Multiple Myelom... | DARATUMUMAB DURVALUMAB | 18 Years - | Celgene | |
| Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | NCT01615029 | Multiple Myelom... | Part 1 (Dose Es... Part 2 (Dose Ex... Lenalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | NCT01615029 | Multiple Myelom... | Part 1 (Dose Es... Part 2 (Dose Ex... Lenalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03477643 | Relapsed and Re... | 18 Years - | PETHEMA Foundation | ||
| Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma | NCT00065351 | Multiple Myelom... | CC-5013 | 18 Years - | Celgene | |
| IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic | NCT03683277 | Multiple Myelom... Relapsed and Re... Genetic Conditi... | Ixazomib/Pomali... | 18 Years - | Intergroupe Francophone du Myelome | |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | NCT02144038 | Relapsed and Re... | LGH447 BYL719 | 18 Years - | Novartis | |
| Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line | NCT01430546 | Multiple Myelom... | 18 Years - | Karolinska University Hospital | ||
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | NCT00932698 | Relapsed and Re... | Ixazomib | 18 Years - | Takeda | |
| Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | NCT01712789 | Multiple Myelom... | Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | NCT03710915 | Multiple Myelom... Relapsed and Re... | HG146 | 18 Years - 75 Years | HitGen Inc. | |
| Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | NCT01712789 | Multiple Myelom... | Pomalidomide Dexamethasone | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
